13 dic 2018

New publications autumn 2018

Since August 2018, three new articles have been published using SCQM data.

  • reproductive and menopausal factors and structural progression of rheumatoid arthritis
  • Tocilizumab use as intravenous or subcutaneous treatment
  • International Consortium for Health Outcomes Measurement ICHOM: towards standardizing physical function outcome

Role of reproductive and menopausal factors in functional and structural progression of rheumatoid arthritis: results from the SCQM cohort, Alpizar-Rodriguez D., Förger F. et al, Rheumatology October 2018

Deshire Alpizar came to Switzerland to work on her doctoral thesis in Axel Finckh’s group. She developed a questionnaire on reproductive factors, which was collected for female patients in the SCQM between July 2015 and July 2017. In this paper, she compared the course of functional disability and radiographic progression by menopausal status at inclusion into the SCQM. Since pre- and post-menopausal women differ in several other risk factors for functional and radiographic progression, they adjusted the analyses for age, disease duration, BMI, smoking, alcohol, educational level and treatment status. Post-menopausal patients had less improvement of HAQ over time than pre-menopausal ones. However, this difference was small and below the minimal important change. The radiographic progression was similar in both groups.

Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries, Lauper K., Mongin D. et al, RMD Open, Sept. 2018

The objective of this European collaborative register study was to compare the real-world effectiveness of tocilizumab (TCZ) in subcutaneous (SC) versus intravenous (IV) therapy. Drug retention, CDAI evolution and one-year CDAI response were analyzed. A total of 3448 patients from eight countries were retrieved, 2414 with TCZ-IV and 1034 with TCZ-SC. Covariates adjusted hazards of discontinuation and CDAI evolution, and attrition-adjusted CDAI response after 12 months were similar with SC and IV therapy of tocilizumab. The authors conclude in light of these results that, for the sake of lower costs, SC should be the preferred mode of application for the use of TCZ.

Towards standardized patient reported physical function outcome reporting: linking ten commonly used questionnaires to a common metric, M. A. H. Oude Voshaar, D. Courvoisier, M. A. F. J. van de Laar et al, Quality of Life Research, September 2018

Several different outcome measures are used in research studies involving inflammatory arthritis (IA) patients. The International Consortium for Health Outcomes Measurement (ICHOM) is a multidisciplinary group, including patients, with the aim of developing standardized patient reported outcome measures (PROMs) that may be globally applicable and that reflect outcomes that matter to patients with IA. This publication focuses on standardizing physical outcome reporting. Data from over 16’000 patients from different cohorts of patients with IA were used. The items of 10 commonly used physical function PROMs were mapped onto a latent physical function variable. This allows any of these physical function PROMs to be converted numerically into the common physical function variable, thus allowing data from different sources to be analysed together.